| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OSUR Stock Overview
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.
Risk Analysis
No risks detected for OSUR from our risk checks.
OraSure Technologies Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.79 |
| 52 Week High | US$13.57 |
| 52 Week Low | US$2.62 |
| Beta | -0.23 |
| 1 Month Change | -35.86% |
| 3 Month Change | -60.26% |
| 1 Year Change | -73.07% |
| 3 Year Change | -69.44% |
| 5 Year Change | -84.00% |
| Change since IPO | -49.27% |
Recent News & Updates
Are OraSure Technologies, Inc. (NASDAQ:OSUR) Investors Paying Above The Intrinsic Value?
How far off is OraSure Technologies, Inc. ( NASDAQ:OSUR ) from its intrinsic value? Using the most recent financial...
OraSure: Not So Sure With Softening Fundamentals, Fairly Priced At $2.54
OraSure has pushed lower on the charts in recent times amid a series of headwinds. Qualitatively there are potential upside catalysts yet to be realized by the stock, however, these look to be well priced in already. Fundamentals have softened in recent years and offer a small portion of unrealized value in earnings and FCF for shareholders. We've priced the stock at $2.54 on a composite of several weighting factors, noting several targets below this mark as well. Here are the moving parts of the OSUR investment debate.
Shareholder Returns
| OSUR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.4% | 3.5% | 1.7% |
| 1Y | -73.1% | -25.7% | -20.4% |
Return vs Industry: OSUR underperformed the US Medical Equipment industry which returned -24% over the past year.
Return vs Market: OSUR underperformed the US Market which returned -18.8% over the past year.
Price Volatility
| OSUR volatility | |
|---|---|
| OSUR Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 10.4% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OSUR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: OSUR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 785 | Carrie Eglinton Manner | https://www.orasure.com |
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company’s principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test.
OraSure Technologies Fundamentals Summary
| OSUR fundamental statistics | |
|---|---|
| Market Cap | US$209.40m |
| Earnings (TTM) | -US$46.74m |
| Revenue (TTM) | US$242.80m |
0.8x
P/S Ratio-4.3x
P/E RatioIs OSUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSUR income statement (TTM) | |
|---|---|
| Revenue | US$242.80m |
| Cost of Revenue | US$139.25m |
| Gross Profit | US$103.55m |
| Other Expenses | US$150.29m |
| Earnings | -US$46.74m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 42.65% |
| Net Profit Margin | -19.25% |
| Debt/Equity Ratio | 0% |
How did OSUR perform over the long term?
See historical performance and comparisonValuation
Is OSUR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OSUR?
Other financial metrics that can be useful for relative valuation.
| What is OSUR's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$209.40m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | -4.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OSUR's PS Ratio compare to its peers?
| OSUR PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.9x | ||
SMTI Sanara MedTech | 6.1x | 36.5% | US$163.6m |
UTMD Utah Medical Products | 6.3x | n/a | US$324.3m |
MHUA Meihua International Medical Technologies | 1.3x | n/a | US$126.9m |
RXST RxSight | 13.8x | 34.1% | US$388.4m |
OSUR OraSure Technologies | 0.8x | -12.5% | US$209.4m |
Price-To-Sales vs Peers: OSUR is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (6.9x).
Price to Earnings Ratio vs Industry
How does OSUR's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: OSUR is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Medical Equipment industry average (4x)
Price to Sales Ratio vs Fair Ratio
What is OSUR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 0.6x |
Price-To-Sales vs Fair Ratio: OSUR is expensive based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Share Price vs Fair Value
What is the Fair Price of OSUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OSUR ($2.79) is trading above our estimate of fair value ($2.02)
Significantly Below Fair Value: OSUR is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OSUR's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
68.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSUR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OSUR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OSUR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OSUR's revenue is expected to decline over the next 3 years (-12.5% per year).
High Growth Revenue: OSUR's revenue is forecast to decline over the next 3 years (-12.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OSUR is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has OraSure Technologies performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-60.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSUR is currently unprofitable.
Growing Profit Margin: OSUR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OSUR is unprofitable, and losses have increased over the past 5 years at a rate of 60.4% per year.
Accelerating Growth: Unable to compare OSUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSUR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: OSUR has a negative Return on Equity (-12.81%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is OraSure Technologies's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: OSUR's short term assets ($268.4M) exceed its short term liabilities ($55.6M).
Long Term Liabilities: OSUR's short term assets ($268.4M) exceed its long term liabilities ($15.1M).
Debt to Equity History and Analysis
Debt Level: OSUR is debt free.
Reducing Debt: OSUR has not had any debt for past 5 years.
Debt Coverage: OSUR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: OSUR has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is OraSure Technologies's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OSUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSUR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSUR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OSUR has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.6yrs
Average management tenure
CEO
Carrie Eglinton Manner (46 yo)
no data
Tenure
Ms. Carrie Eglinton Manner serves as President, Chief Executive Officer & Director of OraSure Technologies, Inc. since June 04, 2022. She joined OraSure Technologies, Inc. on June 04, 2022. She serves as a...
Leadership Team
Experienced Management: OSUR's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
Experienced Board: OSUR's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
OraSure Technologies, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: OraSure Technologies, Inc.
- Ticker: OSUR
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$209.396m
- Shares outstanding: 72.46m
- Website: https://www.orasure.com
Number of Employees
Location
- OraSure Technologies, Inc.
- 220 East First Street
- Bethlehem
- Pennsylvania
- 18015
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/28 00:00 |
| End of Day Share Price | 2022/06/28 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.